Phaseline

Companies › Abscint NV/SA

Abscint NV/SA: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
68Ga-ABS011
single domain antibody (sdAb) targeting HER2 labeled with gallium-68 for PET imaging
ERBB2Phase 2Metastatic Breast CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT0636983168Ga-ABS011Phase 2Metastatic Breast CancerOncologyDec 2026

Targets

ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Pfizer Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Yuhan

Companies built like this

Partner Therapeutics Aston Sci. Chengdu SciMount Pharmatech Hangzhou Converd Beijing Gene Key Life Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.